Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib.
J Thorac Oncol
; 9(11): 1726-8, 2014 Nov.
Article
em En
| MEDLINE
| ID: mdl-25436807
ABSTRACT
The tyrosine kinase inhibitor crizotinib is an effective therapy for patients with cancers harboring rearrangements of the anaplastic lymphoma kinase (ALK) gene. Here, we describe two patients with advanced ALK-positive lung cancer who developed hypersensitivity to crizotinib, requiring temporary discontinuation of the drug. Both patients were treated with a rapid oral desensitization protocol allowing them to resume crizotinib without further signs or symptoms of hypersensitivity.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pirazóis
/
Piridinas
/
Carcinoma Pulmonar de Células não Pequenas
/
Hipersensibilidade a Drogas
/
Neoplasias Pulmonares
/
Antineoplásicos
Tipo de estudo:
Etiology_studies
/
Guideline
Limite:
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
J Thorac Oncol
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Marrocos